354 related articles for article (PubMed ID: 12574425)
1. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.
Cepeda C; Hurst RS; Calvert CR; Hernández-Echeagaray E; Nguyen OK; Jocoy E; Christian LJ; Ariano MA; Levine MS
J Neurosci; 2003 Feb; 23(3):961-9. PubMed ID: 12574425
[TBL] [Abstract][Full Text] [Related]
2. Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.
Parievsky A; Moore C; Kamdjou T; Cepeda C; Meshul CK; Levine MS
Neurobiol Dis; 2017 Dec; 108():29-44. PubMed ID: 28757327
[TBL] [Abstract][Full Text] [Related]
3. Striatal Direct and Indirect Pathway Output Structures Are Differentially Altered in Mouse Models of Huntington's Disease.
Barry J; Akopian G; Cepeda C; Levine MS
J Neurosci; 2018 May; 38(20):4678-4694. PubMed ID: 29691329
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons.
Centonze D; Calabresi P; Pisani A; Marinelli S; Marfia GA; Bernardi G
Neuropharmacology; 1998 Aug; 37(8):1063-70. PubMed ID: 9833635
[TBL] [Abstract][Full Text] [Related]
5. Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease.
Buren C; Parsons MP; Smith-Dijak A; Raymond LA
Neurobiol Dis; 2016 Mar; 87():80-90. PubMed ID: 26711622
[TBL] [Abstract][Full Text] [Related]
6. Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.
Indersmitten T; Tran CH; Cepeda C; Levine MS
J Neurophysiol; 2015 Apr; 113(7):2953-66. PubMed ID: 25673747
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway.
Wu N; Joshi PR; Cepeda C; Masliah E; Levine MS
J Neurosci Res; 2010 Jun; 88(8):1764-76. PubMed ID: 20029978
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.
Klapstein GJ; Fisher RS; Zanjani H; Cepeda C; Jokel ES; Chesselet MF; Levine MS
J Neurophysiol; 2001 Dec; 86(6):2667-77. PubMed ID: 11731527
[TBL] [Abstract][Full Text] [Related]
9. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF.
Cepeda C; Starling AJ; Wu N; Nguyen OK; Uzgil B; Soda T; André VM; Ariano MA; Levine MS
J Neurosci Res; 2004 Dec; 78(6):855-67. PubMed ID: 15505789
[TBL] [Abstract][Full Text] [Related]
10. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
Kolodziejczyk K; Raymond LA
Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
[TBL] [Abstract][Full Text] [Related]
11. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
[TBL] [Abstract][Full Text] [Related]
12. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease.
Joshi PR; Wu NP; André VM; Cummings DM; Cepeda C; Joyce JA; Carroll JB; Leavitt BR; Hayden MR; Levine MS; Bamford NS
J Neurosci; 2009 Feb; 29(8):2414-27. PubMed ID: 19244517
[TBL] [Abstract][Full Text] [Related]
13. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
Farrar AM; Callahan JW; Abercrombie ED
Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
[TBL] [Abstract][Full Text] [Related]
14. The corticostriatal pathway in Huntington's disease.
Cepeda C; Wu N; André VM; Cummings DM; Levine MS
Prog Neurobiol; 2007 Apr; 81(5-6):253-71. PubMed ID: 17169479
[TBL] [Abstract][Full Text] [Related]
15. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease.
Cummings DM; Cepeda C; Levine MS
ASN Neuro; 2010 Jun; 2(3):e00036. PubMed ID: 20585470
[TBL] [Abstract][Full Text] [Related]
16. Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease.
Ghiglieri V; Campanelli F; Marino G; Natale G; Picconi B; Calabresi P
J Neurosci Res; 2019 Dec; 97(12):1655-1664. PubMed ID: 31498496
[TBL] [Abstract][Full Text] [Related]
17. Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.
Dorner JL; Miller BR; Klein EL; Murphy-Nakhnikian A; Andrews RL; Barton SJ; Rebec GV
Brain Res; 2009 Sep; 1290():111-20. PubMed ID: 19616518
[TBL] [Abstract][Full Text] [Related]
18. Altered corticostriatal neurotransmission and modulation in dopamine transporter knock-down mice.
Wu N; Cepeda C; Zhuang X; Levine MS
J Neurophysiol; 2007 Jul; 98(1):423-32. PubMed ID: 17522168
[TBL] [Abstract][Full Text] [Related]
19. Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease.
Sebastianutto I; Cenci MA; Fieblinger T
Neurobiol Dis; 2017 Sep; 105():117-131. PubMed ID: 28578004
[TBL] [Abstract][Full Text] [Related]
20. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
